Observational Study of Peritoneal Washing Cytology-Positive Gastric Cancer without Gross Peritoneal Metastasis in Patients who Underwent Radical D2 Gastrectomy

Shim, Hyungbo; Kim, Hyeonjong; Lee, Seung Hyuk; Bae, Woo-Kyun; Hwang, Eu Chang; Cho, Sang‐Hee; Chung, Ik‐Joo; Bang, Hyun-Jin; Hwang, Jun Eul

doi:10.1038/s41598-020-66637-y

Cited by 18 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, the study documented the benefit of adjuvant S-1 monotherapy, as the median survival increased to 22.3 mo compared to 11.8 mo in the surgery alone group[ 19 ]. The benefit of adjuvant therapy was confirmed in another study from Korea by Shim et al [ 20 ]. Adjuvant chemotherapy by TS-1 ± cisplatin or oxaliplatin plus capecitabine (XELOX) or oxaliplatin + 5-FU (FOLFOX) improved median disease-free survival (DFS) (11.63 vs 6.98 mo, P < 0.001) and OS (25.50 vs 12.11 mo, P < 0.001)[ 20 ].…”

Section: Upfront Surgery For Cy1 Gc Patientsmentioning

confidence: 73%

“…The benefit of adjuvant therapy was confirmed in another study from Korea by Shim et al [ 20 ]. Adjuvant chemotherapy by TS-1 ± cisplatin or oxaliplatin plus capecitabine (XELOX) or oxaliplatin + 5-FU (FOLFOX) improved median disease-free survival (DFS) (11.63 vs 6.98 mo, P < 0.001) and OS (25.50 vs 12.11 mo, P < 0.001)[ 20 ]. No significant differences were observed between the regimen of postoperative chemotherapy and survival[ 20 ], thus the most optimal regimen remains unclear.…”

Section: Upfront Surgery For Cy1 Gc Patientsmentioning

confidence: 73%

“…Adjuvant chemotherapy by TS-1 ± cisplatin or oxaliplatin plus capecitabine (XELOX) or oxaliplatin + 5-FU (FOLFOX) improved median disease-free survival (DFS) (11.63 vs 6.98 mo, P < 0.001) and OS (25.50 vs 12.11 mo, P < 0.001)[ 20 ]. No significant differences were observed between the regimen of postoperative chemotherapy and survival[ 20 ], thus the most optimal regimen remains unclear. Another retrospective study by Komatsu et al [ 21 ] analyzed upfront gastrectomy followed by adjuvant S-1 based chemotherapy in 51 Cy1 GC patients, with a special focus on the impact of surgical radicality.…”

Section: Upfront Surgery For Cy1 Gc Patientsmentioning

confidence: 99%

See 2 more Smart Citations

Current treatment strategies for patients with only peritoneal cytology positive stage IV gastric cancer

Baušys¹,

Gricius²,

Aniukstyte³

et al. 2021

WJCC

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most common malignancies worldwide and surgery remains the only potentially curative treatment option for it. Although a significant proportion of GC patients are found with distant metastases already at the initial diagnosis. Peritoneal dissemination is the most common site of metastases. Positive peritoneal cytology (Cy1) is associated with poor long-term outcomes; thus, these patients are considered as stage IV even if macroscopic carcinomatosis is absent. Currently, there is no clear evidence for the most optimal treatment for this distinct subpopulation of the stage IV cohort. Available strategies vary from palliative chemotherapy to upfront gastrectomy. This comprehensive review summarized current evidence of different treatment strategies for Cy1 GC including roles of surgery, systemic and intraperitoneal chemotherapy.

show abstract

Section: Upfront Surgery For Cy1 Gc Patientsmentioning

confidence: 73%

Section: Upfront Surgery For Cy1 Gc Patientsmentioning

confidence: 73%

Section: Upfront Surgery For Cy1 Gc Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Current treatment strategies for patients with only peritoneal cytology positive stage IV gastric cancer

Baušys¹,

Gricius²,

Aniukstyte³

et al. 2021

WJCC

View full text Add to dashboard Cite

show abstract

“…Recent studies have found that positive abdominal cytology is an important factor affecting the prognosis of patients with GC ( 66 , 67 ). A recent study found postoperative chemotherapy can improve the survival rate of GC patients with positive peritoneal cytology ( 68 ).…”

Section: Discussionmentioning

confidence: 99%

hsa_circ_0060975 is highly expressed and predicts a poor prognosis in gastric cancer

Zhang

et al. 2021

Oncol Lett

View full text Add to dashboard Cite

Gastric cancer (GC) is the fifth most common cancer and GC has a high mortality rate worldwide. Circular (circ) RNAs serve an important role in cancer. The present study aimed to investigate the expression level of hsa_circ_0060975 in gastric cancer (GC) and to determine the clinical pathological significance of hsa_circ_0060975 in patients with GC. Reverse transcription-quantitative PCR was used to detect expression level of hsa_circ_0060975 in 192 GC and adjacent non-cancerous gastric tissues, in GC cell lines (MKN-45, HGC27 and AGS) and a human gastric epithelium cell line (GES-1), as well as in plasma samples from 126 patients with GC and 92 healthy volunteers. All plasma and tissue samples of were obtained from The First Affiliated Hospital of Anhui Medical University (Hefei, China). The relationship between hsa_circ_0060975 expression and clinical pathological factors was analyzed using the χ 2 test. The diagnostic value of hsa_circ_0060975 was analyzed using the receiver operating characteristic curve (ROC curve), while the Kaplan-Meier method was used to analyze the relationship of hsa_circ_0060975 expression with the survival of patients with GC as determined by log-rank tests. Univariate and multivariate Cox regression analyses were used to identify the prognostic factors, including hsa_circ_0060975 expression and clinical pathological factors. In addition, the potential function of hsa_circ_0060975 was evaluated via bioinformatics analysis. The expression level of hsa_circ_0060975 was higher in GC tissues compared with adjacent non-cancerous gastric tissues, GC cell lines compared with GES-1 and plasma samples from patients with GC compared with plasma samples from healthy volunteers. In addition, higher hsa_circ_0060975 expression was associated with histological grade, pathological stage and tumor (T) classification in GC tissues and plasma samples (P<0.05). The area under the ROC curves of hsa_circ_0060975, the combination with hsa_circ_0060975 and carcinoembryonic antigen (CEA) or CEA alone were 0.804 (sensitivity, 0.746; specificity, 0.783; P<0.001); 0.931 (sensitivity, 0.937; specificity, 0.870; P<0.001) and 0.924 (sensitivity, 0.937; sspecificity, 0.804; P<0.001) respectively. The Kaplan-Meier survival analysis revealed that the overall survival (OS) and disease-free survival (DFS) time of patients with higher hsa_circ_0060975 expression were shorter compared with those in patients with lower hsa_circ_0060975 expression. Univariate and multivariate Cox regression analyses in OS and DFS time determined that the expression level of hsa_circ_0060975, histological grade and pathological stage were independent prognostic factors for patients with GC. In addition, the bioinformatics analysis results suggested that the abnormal expression of hsa_circ_0060975 may serve an important role in tumorigenesis. Hence, hsa_circ_0060975 expression may be an independent prognostic factor for patients with GC and may be a potential marker for biological malignancy.

show abstract

“…For GC patients with positive cytology, but without gross peritoneal metastases, no clear therapeutic strategies have yet been established. Studies conducted by Hyun-Jeong et al [ 24 ] have shown that postoperative chemotherapy improves the survival outcome compared to surgery alone in GC patients who underwent radical D2 gastrectomy. Since the presence of FCC in the peritoneal fluid/lavage influences further therapeutic decisions, it is important that the test result is reliable.…”

Section: Discussionmentioning

confidence: 99%

Rapid Detection of Free Cancer Cells in Intraoperative Peritoneal Lavage Using One-Step Nucleic Acid Amplification (OSNA) in Gastric Cancer Patients

Gęca

Rawicz‐Pruszyński

Mielko

et al. 2020

Cells

View full text Add to dashboard Cite

Cytokeratin-19 (CK19) has been proven to be commonly expressed by cancer cells in a variety of solid tumors and may serve as a suitable marker of metastases in gastric cancer (GC). Since objective assessment of peritoneal lavage or fluid for free cancer cells (FCC) is essential for clinical decision making in patients with GC, it is important to develop a quantitative and reproducible method for such evaluation. We assessed the possible application of One-Step Nucleic Acid amplification (OSNA) assay as a rapid method for FCC detection in intraoperative peritoneal lavage or fluid of GC patients. Seventy-eight intraoperative peritoneal lavage or fluid samples were eligible for the analysis by conventional cytology and OSNA examination. The concentration of CK19 mRNA in intraoperative peritoneal lavage and fluid was compared with the conventional cytological assessment. CK19 mRNA concentration was detected by OSNA assay. For peritoneal lavage samples, sensitivity and specificity were 83.3% and 87.8%, respectively. In peritoneal fluid, significantly higher CK19 values were observed in patients with serosal infiltration (medians: 100 copies/µL vs. 415.7 copies/µL; p = 0.0335) and lymph node metastases (medians: 2.48 copies/µL vs. 334.8 copies/µL). OSNA assay turns out to be an objective, fast, and reproducible quantitative method of FCC assessment.

show abstract

Observational Study of Peritoneal Washing Cytology-Positive Gastric Cancer without Gross Peritoneal Metastasis in Patients who Underwent Radical D2 Gastrectomy

Cited by 18 publications

References 23 publications

Current treatment strategies for patients with only peritoneal cytology positive stage IV gastric cancer

Current treatment strategies for patients with only peritoneal cytology positive stage IV gastric cancer

hsa_circ_0060975 is highly expressed and predicts a poor prognosis in gastric cancer

Rapid Detection of Free Cancer Cells in Intraoperative Peritoneal Lavage Using One-Step Nucleic Acid Amplification (OSNA) in Gastric Cancer Patients

Contact Info

Product

Resources

About